23 unknown. 23 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Unknown 23 |
| Phase 2 | 10 | Unknown 10 |
Follow Motor Neuron Disease: new trials by email Literature Review of Motor Neuron Disease trials Research Report on Motor Neuron Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis Aleeto, intravenous injection, intrathecal injection - Amyotrophic Lateral Sclerosis | Phase 1 | Unknown | Beijing Tiantan Hospital | 24 | 2023-12-15 | 2023-12-26 |
| Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS) [18F]-RoSMA-18-d6 - Amyotrophic Lateral Sclerosis | Phase 1 | Unknown | Markus Weber | 30 | 2023-08-01 | 2023-05-30 |
| Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris topical minoxidil in Acne Vulgaris - Acne Vulgaris | Phase 1 / Phase 2 | Unknown | Chang Gung Memorial Hospital | 26 | 2023-07-11 | 2023-11-03 |
| Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1 EXG001-307 injection - Spinal Muscular Atrophy Type I | Phase 1 / Phase 2 | Unknown | Guangzhou Jiayin Biotech Ltd | 12 | 2023-02-16 | 2024-09-19 |
| Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS AMX0035 - ALS | Phase 1 / Phase 2 | Unknown | Amylyx Pharmaceuticals Inc. | 14 | 2021-08-05 | 2023-07-24 |
| The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS Mesenchymal stem cells isolated from Wharton's jelly - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Unknown | Polski Bank Komorek Macierzystych JSC (PBKM) | 20 | 2020-12-02 | 2022-05-03 |
| A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS) AP-101 - Amyotrophic Lateral Sclerosis | Phase 1 | Unknown | AL-S Pharma | 18 | 2019-10-10 | 2020-10-27 |
| ALS Treatment Extension Study Cu(II)ATSM - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Unknown | Collaborative Medicinal Development Pty Limited | 28 | 2018-01-18 | 2022-02-17 |
| CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS CC100, Placebos - Amyotrophic Lateral Sclerosis | Phase 1 | Unknown | Chemigen, LLC | 21 | 2017-04-07 | 2017-08-03 |
| Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS HYNRCS-Allo inj - Amyotrophic Lateral Sclerosis | Phase 1 | Unknown | Hanyang University Seoul Hospital | 6 | 2017-02-01 | 2019-05-16 |
| Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Stem Cells - Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Unknown | Stem Cells Arabia | 40 | 2016-09-01 | 2018-06-06 |
| Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis Two intrathecal MSC injections - AMYOTROPHIC LATERAL SCLEROSIS | Phase 1 / Phase 2 | Unknown | University of Sao Paulo General Hospital | 28 | 2016-09-01 | 2016-09-28 |
| Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis recombinant human erythropoietin(rhEPO) - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Unknown | Hanyang University Seoul Hospital | 64 | 2016-06-20 | 2019-02-08 |
| Therapeutic Treatment of Amyotrophic Lateral Sclerosis Biological: Cell-based therapy - Amyotrophic Lateral Sclerosis | Phase 1 | Unknown | University of Warmia and Mazury | 30 | 2015-11-01 | 2016-08-29 |
| Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis Biological: Cell-based therapy - Amyotrophic Lateral Sclerosis | Phase 1 | Unknown | University of Warmia and Mazury | 30 | 2015-11-01 | 2016-08-29 |
| Intraspinal Transplantation of Autologous ADRC in ALS Patients Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients - Amyotrophic Lateral Sclerosis | Phase 1 | Unknown | Mossakowski Medical Research Centre Polish Academy of Sciences | 30 | 2015-10-13 | 2020-04-15 |
| Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients Adipose derived mesenchymal stem cell - Infantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman] | Phase 1 / Phase 2 | Unknown | Tehran University of Medical Sciences | 10 | 2015-06-01 | 2016-08-04 |
| Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis MNC (Mononuclear cells), Saline - ALS (Amyotrophic Lateral Sclerosis) | Phase 1 | Unknown | Red de Terapia Celular | 20 | 2014-11-01 | 2017-03-30 |
| Determining the Safety of L-serine in ALS L-Serine - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Unknown | Phoenix Neurological Associates, LTD | 20 | 2013-01-01 | 2015-07-30 |
| Biological Treatment of Amyotrophic Lateral Sclerosis Biological: Cell-based therapeutics, Symptomatic treatment of ALS - Amyotrophic Lateral Sclerosis | Phase 1 | Unknown | Pomeranian Medical University Szczecin | 50 | 2010-01-01 | 2014-07-18 |
Showing 20 of 23. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (20) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2) · Spinal Muscular Atrophies of Childhood (2) · Acne Vulgaris (1) · Amyotrophic lateral sclerosis 1 (1) · Bulbar Palsy, Progressive (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Central Nervous System Diseases (1) · Muscular Atrophy, Spinal (1) · Nervous System Diseases (1) · Sclerosis (1) · Spinal Diseases (1)
Spinal Cord Diseases (23) · Central Nervous System Diseases (22) · Nervous System Diseases (22) · Neurodegenerative Diseases (21) · Neuromuscular Diseases (21) · Metabolic Diseases (20) · Nutritional and Metabolic Diseases (20) · Proteostasis Deficiencies (20) · TDP-43 Proteinopathies (20) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Heredodegenerative Disorders, Nervous System (3) · Muscular Atrophy, Spinal (3) · Acneiform Eruptions (1)
Cell- and Tissue-Based Therapy (1) · Copper (1) · Injections, Intravenous (1) · Injections, Spinal (1) · Minoxidil (1) · Serine (1) · Sodium Chloride (1) · copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) (1) · sodium phenylbutyrate and taurursodiol (1)
Hanyang University Seoul Hospital (2) · University of Warmia and Mazury (2) · AL-S Pharma (1) · Amylyx Pharmaceuticals Inc. (1) · Beijing Tiantan Hospital (1) · Chang Gung Memorial Hospital (1) · Chemigen, LLC (1) · Collaborative Medicinal Development Pty Limited (1) · GAAD Medical Research Institute Inc. (1) · Guangzhou Jiayin Biotech Ltd (1) · Markus Weber (1) · Mossakowski Medical Research Centre Polish Academy of Sciences (1) · Neuralstem Inc. (1) · Phoenix Neurological Associates, LTD (1) · Polski Bank Komorek Macierzystych JSC (PBKM) (1)
United States (4) · Poland (3) · Canada (2) · China (2) · South Korea (2) · Australia (1) · Brazil (1) · France (1) · Iran (1) · Spain (1) · Switzerland (1) · Taiwan (1)
Wojciech Maksymowicz, MD, Prof. (2) · Amir Ali Hamidieh, MD (1) · Boguslaw Machalinski, MD, PhD (1) · Cheng-Lung Hsu, Profesor (1) · Dominic Rowe, MD (1) · Gerson Chadi, MD, PhD (1) · Ken Nedd, M.D. (1) · Mahmoode Reza Ashrafi, MD (1) · Przemyslaw Nowacki, MD, PhD (1) · Rashin Mohseni, PhD (1) · Seung Hyun Kim, M.D.,Ph.D. (1)
PMID 11050032, PMID 15084121, PMID 17978354, PMID 22415942, PMID 22415951, PMID 22565043, PMID 23300829, PMID 23463272, PMID 24820540, PMID 25324884, PMID 30158984, PMID 30531015, PMID 31629403, PMID 32265627, PMID 40458203